Clinical Trial Update: Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial [Phase 2]

View source ↗

Summary

Phase 2 multicenter randomized, placebo-controlled trial evaluating low-dose interleukin-2 for systemic lupus erythematosus has completed, reporting efficacy an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED